


LISTING OF CLAIMS

1. (Original) A compound of formula (I)




or a pharmaceutically acceptable salt, solvate or derivative thereof.

2. (Original) A pharmaceutical composition comprising the compound according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.
3. (Cancelled).
4. (Cancelled).
5. (Original) A compound according to claim 1 for use as a reverse transcriptase inhibitor or modulator.
6. (Original) A composition according to claim 2 for use as a reverse transcriptase inhibitor or modulator.
7. (Original) A compound according to claim 1 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).
8. (Original) A composition according to claim 2 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

9. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound according to claim 1.




10. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a composition according to claim 2.

11. (Withdrawn) A process for preparing the compound of formula (I)




or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

(A) condensing a compound of formulae (II), (VI) or (VII)




wherein  $L^1$  and  $L^2$  are leaving groups;

with the compound of formula (V)




or a salt or hydrate thereof;

(B) alkylating the pyrazole of formula (XIII)



with an alkylating agent of formula (XIV)




or a protected derivative thereof;

(C) deprotecting a protected derivative of the compound of formula (I);


and optionally converting the compound of formula (I) prepared by any one of steps (A) to (C) into a pharmaceutically acceptable salt, solvate or derivative thereof.

12. (Withdrawn) A process according to claim 11 wherein  $L^1$  and  $L^2$  are each independently selected from  $-N(C_1-C_6 \text{ alkyl})_2$  and  $-N(CH_3)_2$ .

13. (Withdrawn) A compound of formula (II)




14. (Withdrawn) A compound of formula (VI)



wherein  $L^1$  is a leaving group.


15. (Withdrawn) A compound of formula (VII)




wherein L<sup>2</sup> is a leaving group.

16. (Withdrawn) A compound according to claim 14 or 15 wherein L<sup>1</sup> and L<sup>2</sup> are each independently selected from -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub> and -N(CH<sub>3</sub>)<sub>2</sub>.

17. (Withdrawn) A compound of formula (VIII)



18. (Withdrawn) A compound of formula (IX)



19. (Original) A compound of formula (XIII)

